SCHEMBL167080

SCHEMBL167080

NC(=O)c1cccc(-c2ccccn2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 3/20 0.57
KDM1A O60341 1/20 0.54
HPGDS O60760 1/20 0.53
KAT6A Q92794 2/20 0.52
PRKCI P41743 1/20 0.51
CYP2A6 P11509 1/20 0.50
CNR1 P21554 1/20 0.50
FYN P06241 3/20 0.49
CCNT1 O60563 1/20 0.49
CCND1 P24385 1/20 0.49
CCNC P24863 1/20 0.49
CDK8 P49336 1/20 0.49
CDK7 P50613 1/20 0.49
CDK9 P50750 1/20 0.49
CCNH P51946 1/20 0.49
MNAT1 P51948 1/20 0.49
CDK6 Q00534 1/20 0.49
KDM4E B2RXH2 1/20 0.49
KDM6B O15054 1/20 0.49
KDM4A O75164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036208 1.00 CHEK2 (0.57) CHEK2KDM1AHPGDSKAT6APRKCI
Dipyridyl SCHEMBL28724644 0.89 KDM4E (0.56) CHEK2KDM4EKDM6BKDM4AKDM5C
SCHEMBL4631461 0.85 PRKCI (0.54) CHEK2KDM1AHPGDSKAT6APRKCI
SCHEMBL5108635 0.85 KAT6A (0.55) KAT6ACYP2A6CNR1KDM4EKDM6B
SCHEMBL29800516 0.84 KDM4E (0.69) KAT6ACYP2A6CNR1KDM4EKDM6B
SCHEMBL4927431 0.84 CHEK2 (0.67) CHEK2PARP1ABL1DHODH
SCHEMBL207017 0.84 KDM4E (0.69) KAT6ACYP2A6CNR1KDM4EKDM6B
SCHEMBL2457556 0.84 KAT6A (0.54) KAT6ACYP2A6CNR1KDM4EKDM6B
SCHEMBL31301228 0.83 CHEK2 (0.59) CHEK2HPGDSCYP2A6KDM4EKDM6B
SCHEMBL28334001 0.83 CHEK2 (0.59) CHEK2HPGDSCYP2A6KDM4EKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023069727-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS EDISON ONCOLOGY (US) 2023-04-27 WO claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-2344486-B1 ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THEIR USE AS FAAH INHIBITORS SANOFI SA (FR) 2013-03-27 EP disclosed
WO-2011038572-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-04-07 WO disclosed
WO-2010010288-A2 ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-01-28 WO disclosed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 CHEK2 4667/4885KDM1A 2484/4885HPGDS 1109/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 CHEK2 4667/4885KDM1A 2484/4885HPGDS 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.